Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease

计划入组 8 人 · 首次发布于 2020 年 6 月 2 日

A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

计划入组 240 人 · 首次发布于 2025 年 5 月 30 日

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

计划入组 114 人 · 首次发布于 2019 年 6 月 6 日

CoV2-PGEN1

Alzheimer's Research Gains Momentum with Genetic Studies and Lecanemab Approval

Alzheimer's Disease Therapeutics: Donanemab Dosing, Anti-Tau Antibody E2814, and Combination Intranasal Insulin/Empagliflozin Show Promise

Debate Intensifies Over Alzheimer's Cause: Amyloid Plaques vs. Intracellular Pathology